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OBJECTIVES: To identify response shift using two structural equation modeling
(SEM) techniques with the SF-36 Health Survey.METHODS: Hypertensive patients
with coronary artery disease (CAD) who completed both baseline and one year
follow-up of the SF-36 were included (n909). An occurrence of response shift
using Oort and Schmitt SEM techniqueswas specifically identified. LISREL software
was used to conduct SEM procedures. A variety of fit indices were used to deter-
mine model fit. For both SEM approaches, response shift is defined based on
changes in various parameters in themeasurementmodel. Effect size indices were
calculated for the contribution of response shift on the change of SF-36 domains
scores.We hypothesized the divergence in defining type of response shift linked to
changes in various parameters will lead to different findings. RESULTS: Only the
SF-36 physical functioning (PF) scale was identified with recalibration response
shift by using both Oort and Schmitt SEM approaches. With Oort approach, recali-
bration was identified by the change in intercepts, whereas Schmitt approach de-
fines recalibration as the change in factor variances or factor loadings over time.
Effect size of the recalibration response shift on the change of PF domain scores
was marginal: 0.118. CONCLUSIONS: This is the first study to identify response
shift in hypertensive CAD patients using SEM approach. Recalibration response
shift was identified using both Oort and Schmitt SEM approaches. Different inter-
pretation of specific PF items by hypertensive CAD patients before and after treat-
ments may contribute to the recalibration response shift. By looking more closely
at the SF-36 PF domain scores among hypertensive CAD patients will enable us to
provide nuanced attention and direct treatment for the most impaired aspects of
quality of life.
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EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH
LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT
Na Y, Lee EK
Sookmyung Women’s University, Seoul, South Korea
OBJECTIVES: A new drug fimasartan had been developed and currently approved
in Korea for treating essential hypertension. This study aimed to identify whether
main results of direct comparative study maintains consistency with those of ex-
tension of meta-analysis in the blood pressure lowering effect of fimasartan with
losartan. METHODS: Systematic reviews of literatures of clinical trials including
fimasartan or losartan were conducted. The blood pressure change from baseline
were used as an effectiveness measure and was pooled in RevMan 4.0. For direct
comparison, the head-to-head randomized controlled trial (RCT) of fimasartan and
losartan was used. For indirect comparison, it followed to method of adjusted
indirect comparison (Bucher 1997) using common comparator and used ITC (Indi-
rect Treatment Comparison) program (CADTH). In addition, Bayesian mixed treat-
ment comparison (MTC) was performed on which combines whole pairwise com-
parison studies together by WinBugs program. After that, the results were
compared with that of a direct comparison. RESULTS: In regard to direct compar-
ison, there is the only head-to-head trial (Phase III) report of comparing fimasartan
with losartan, which had conducted locally. For indirect comparison, the search
identified one report of the trial of comparing fimasartan with placebo (Phase IIb),
and the 6 of articles of comparing losartan with placebo were selected and mea-
sured estimateswere pooled. The change in reduction in diastolic blood pressure of
losartan and fimasartan versus placebo was 2.7 mmHg as direct estimate re-
trieved from RCT, and3.315 mmHg as combined estimate through MTC analysis,
respectively. In SBP reduction, it was 4.3 mmHg and 3.995 mmHg respectively.
CONCLUSIONS: This study found that estimates obtained from indirect compari-
son were similar with those of direct. The results from the two comparison meth-
ods both indicated consistently that the antihypertensive effect of fimasartan is
better than losartan.
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STEVENS-JOHNSON AND RED MAN SYNDROME: A CASE REPORT ON ADVERSE
DRUG REACTIONS OF SIMULTANEOUS USE OF PHENYTOIN AND VANCOMYCIN
Kler SK
Department of General Medicine, Government Medical College & Hospital, Chandigarh, India
OBJECTIVES: Adverse drug reactions (ADRs) are a common cause of injury to hos-
pitalized patients and are likely preventable.Monitoring spontaneous adverse drug
reactions is one of the epidemiological methods for assessing the safety of drugs in
a hospital setting. Many studies reported that cutaneous reactions and gastroin-
testinal disturbances as top most reported ADRs.METHODS: The author reports a
case of 22-year-old girl who developed Stevens-Johnson syndrome and Red Man
syndrome after receiving phenytoin and vancomycin simultaneously. RESULTS:
This was 22 year old girl presented with chief complaints of headache, nausea,
vomiting and sweating. Diagnosed as a case of post fossa tumor and operated on 3rd
day after admission. She was treated with different medications along with van-
comycin 1gm 12hourly, phenytoin 100mg 8 hourly and dexamethasone 2gm 8
hourly. On the day 15 of vancomycin and phenytoin treatment, the patient devel-
oped diffuse polymorphic erythemawithmouth lesions and typical palmo-plantar
lesions characteristic of Stevens-Johnson syndrome. Also a skin rash and lesions
predominantly on the face, neck, upper back and front regions characterized as Red
Man syndrome. Use of vancomycin and phenytoin was discontinued and replaced
by cefipime plus linizolid and phenobarbitone respectively. The reaction persisted
for approximately 55 days with progressive improvement and the patient was
treated with hydroxyzine 30mg, 6 hourly, hydrocortisone 100mg, 6 hourly with
gradual tapering of the dose and topical treatment of the lesions. CONCLUSIONS:
Although there are reports on the of adverse drug reaction with monotherapy of
phenytoin and vancomycin or in involvement with other medications. However,
there are no reports on the development of Stevens-Johnson and Red man syn-
drome when phenytoin and vancomycin were used simultaneously with other
drug treatment. It also confirms the possible increased risk of developing Stevens-
Johnson syndrome when phenytoin is associated to corticosteroids.
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DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND
ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES
Schaumberg DA1, Li JZ2
1Brigham and Women’s Hospital, Boston, MA, USA, 2Pfizer, Inc., San Diego, CA, USA
OBJECTIVES: To examine factors associated with dry eye disease (DED) in the US.
METHODS: We conducted a cross-sectional survey of 4000 participants in the
Women’s Health Study and Physicians’ Health Studies with diagnosed DED or
severe symptoms. We assessed the current level of symptoms by the Ocular Sur-
face Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) question-
naires, diagnosis, co-morbidities, treatments, and patient satisfaction. RESULTS:
3390 (84.8%) subjects returned questionnaires. 2099 participants reported a diag-
nosis of DED, and 1291 denied DED diagnosis (73.9% of these had reported DED
diagnosis previously). Among 451 subjects selected based on severe symptoms
alone, 114 (25.3%) reported a new diagnosis of DED, which was more strongly
associated with severe symptoms by SANDE40 (OR2.24, p0.001), than by OSDI
33-100 (OR1.38, p0.25). Blepharitis (OR2.03, p0.05) was also associated with
new DED diagnoses. Among those who currently denied DED diagnosis, 15.9% had
severe (SANDE40) and 40.4% had mild-moderate symptoms (SANDE 15-40). Ad-
justing for age and sex, participants with symptoms only were less likely than
diagnosed patients to have an eye exam 1x/year (OR0.71, p0.002), use antide-
pressants (OR0.76, p0.04), artificial tears (OR0.67, p0.0002), or other DED
treatments (OR0.65, p0.0001); and more likely to report refractive surgery
(OR1.67, p0.02), and contact lens wear (OR2.51, p0.0001). In age- and sex-
adjusted models including all respondents, those who currently reported DED di-
agnoses were more likely to have an eye exam 1x/year (OR1.42, p0.0003),
severe symptoms (SANDE 40, OR2.00, p0.0001), blepharitis (OR1.41,
p0.007), use antidepressants (OR1.43, p0.003), artificial tears (OR2.01,
p0.0001), or other DED treatments (OR1.70, p0.0001); and less likely to use
glaucomamedications (OR0.82, p0.02).CONCLUSIONS:These observations sug-
gest the possibility of under-diagnosis of DED, and are also consistentwith amilder
and/or more intermittent type of DED. Individuals with diagnosed DED are more
likely to have severe symptoms, despite therapy.
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PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR
DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL
Chodick G, Shalev V, Goldstein I, Sror M
Maccabi Healthcare Services, Tel Aviv, Israel
OBJECTIVES: To investigate the association between persistent use of statins and
the risk of age-related macular degeneration (AMD). METHODS: A population-
based retrospective cohort among adults who began statin therapy between 1998
and 2006 in a large health organization in Israel. The organization’s central com-
puterized databases were used to collect sata on incident AMD cases diagnosed by
ophthalmologists. RESULTS: A total of 108,973 individuals aged 55 or older were
identified. During the study follow-up period 409,113 person-years, there were
2,732 incident AMD cases (6.68 per 1,000 person-years). The crude incidence den-
sity rate of AMD among patients at the lowest quintile of persistence with statins
(7.18 per 1,000) was comparable to that of highest persistence quintile (7.13 per
1,000). After adjustment for potential confounders, patients in the highest quintile
of persistence with statins had a hazard ratio of 0.99 (95% CI: 0.78-1.26) for AMD
compared with patients in the lowest PDC quintile. In addition to age, AMD was
found to associate with past smoking, asthma, diabetes and frequent visits to
ophthalmologists or primary physicians prior to index date. CONCLUSIONS: Our
study agrees with previous studies that showed no association between persistent
use of statins and reduced risk of AMD. These results suggest that the early reports
on a strong protective effect of statins against AMD development, were probably a
result of a small study effect.
PSS4
SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC LITERATURE ON ATOPIC
DERMATITIS IN CHILDREN
Berbari J1, Reynolds S1, Heil-Ruess M2, Iskedjian M3
1PharmIdeas Research and Consulting, Ottawa, ON, Canada, 2MHR - Nutrition Marketing
Services, Lausanne, Switzerland, 3PharmIdeas Research and Consulting, Oakville, ON, Canada
OBJECTIVES: A systematic review of the literature was performed to gather the
epidemiological evidence related to atopic dermatitis (AD) in a pediatric
population. METHODS: OVID MEDLINE® was searched using terms related to AD,
epidemiology, incidence/prevalence in a population 18 years old. Two research-
ers undertook the inclusion/exclusion process on the 466 citations that had been
identified. A third person acted as an overall reviewer and adjudicator. RESULTS:
The major finding was the International Study of Asthma and Allergies in Child-
hood (ISAAC)which reported the prevalence of AD in children 6-7 years old from 35
countries at two distinct time periods (around 1995 and 2002). A further 32 inde-
pendent studieswere identified for inclusion in this review. These studies reported
on incidence (n2), prevalence (n25) or both (n5) in Europe (n23), Southeast
Asia (n8) and Africa (n1). The number of study participants differed greatly
(n137 to n317,926). According to ISAAC, the worldwide prevalence rate of AD
increased by a rate of 36% from 12.9% in 1995 to 17.5% in 2002. Over that same time
period, a 46% increase was reported for North America and Western Europe with
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the largest increase (95%) observed in LatinAmerica. By 2002,many (n9) countries
had reached absolute prevalence rates  30%. The high prevalence of AD as re-
ported by ISAAC was confirmed in the remaining literature, especially in a popu-
lation of young children and infants, with rates of up to 60%. The reported inci-
dence rates for a similar population were as high as approximately 10%.
CONCLUSIONS: AD is one of the most prevalent disease conditions in childhood,
with an increasing trend in most parts of the world.
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WHAT INFLUENCES DENTAL CARE AMONG CHILDREN?
Hufstader M1, Vaidya V2, White-Means S3, Dishmon B4, Sudharshan L5, Sharma G5
1Covance, gaithersburg, MD, USA, 2University of Toledo, Toledo, OH, USA, 3University of
Tennessee, Memphis, TN, USA, 4Paradigm Dental, Memphis, TN, USA, 5Covance Market Access
Services, Inc., Gaithersburg, MD, USA
OBJECTIVES: The objective was to examine the factors that influence dental care,
dental expenditures, and dental insurance among children (2-17) in the US. Dental
caries are the most prevalent childhood chronic disease. Lack of dental care in
childhood can lead to poor health outcomes and decreased quality of life.
METHODS: The Medical Expenditure Panel Survey data (2008), descriptive statis-
tics, linear regression, and logistic regression were used to perform a cross sec-
tional retrospective analysis. Covariates included race, residence, insurance status,
and family income. RESULTS: Mean dental expenditures per child in 2008 was
$1,246. Half (52%) of children had dental insurance, and half (54%) used preventa-
tive dental services. Children that utilized preventative services had annual mean
dental expenditures ($559) that were significantly lower than children that did not
utilize preventative services ($2,092). Logistic regression analysis indicated that
children without caries were more likely (OR: 2.43 [2.42-2.44]) to have preventative
care than children with caries. Higher income and dental insurance were positive
predictors of preventative dental care. Those with dental insurance had higher
mean annual expenditures ($1,579) compared with those uninsured ($975), indi-
cating that dental insurance increases dental resource use. Predicting factors for
dental insurance were lack of caries, preventative service utilization, higher in-
come, residence in theNortheast orMidwest, Asian descent, andwhite race. Linear
regression showed that dental expenditures were lower among those without
dental insurance, with preventative services, residing in a non-metropolitan
statistical area, black race, Hispanic ethnicity, and residing outside the
northeast. CONCLUSIONS: The data indicate that dental insurance is not the only
barrier to children’s dental care. Certain racial and ethnic groups and lower familial
income are negative predictors for dental care. Preventative services lower dental
expenditures and prevent caries. Therefore the return on investment for preven-
tative services is positive. Health reform should enact policies encouraging preven-
tative dental services.
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SAFETY PROFILE OF LATANOPROST VERSUS TIMOLOL IN PATIENTS WITH
OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION: POST 2000 SETTING
Gupta J, Siddiqui MK, Jindal R, Sehgal M
Heron Health Private Ltd, Chandigarh, Chandigarh, India
OBJECTIVES: To systematically compare the safety of latanoprost versus timolol
through meta-analysis of randomized controlled trials (RCTs) in open angle glau-
coma (OAG) or ocular hypertension (OH). METHODS: Medline and Cochrane Cen-
tral Register of Controlled Trials (CCTR) were searched for RCTs published post
2000, assessing head to head comparison of latanoprost vs. timolol in OAG or OH.
Studies were assessed for inclusion/exclusion based on a prespecified protocol.
Two reviewers undertook data extraction independently. Any disagreement was
resolved by a third reviewer. A customized spreadsheet was used to extract the
relevant outcomes, including the study duration, sample size, number of patients
with local and systemic side effects and the proportion of withdrawals due to
adverse events. RESULTS: Four RCTs enrolling 1688 patients met the inclusion
criteria out of the 289 studies identified. Latanoprost was associated with an in-
creased incidence of hyperemia (risk ratio (RR)  2.7, 95% CI  1.37 to 5.28), iris
pigmentation (RR  10.81, 95% CI  1.37 to 85.47) and pruritus (RR  3.05, 95% CI 
1.06 to 8.73) compared to timolol (Level I evidence). Also, one RCT (Level II evidence)
reported that latanoprost was associated with increased incidences of eyelash
changes (risk difference (RD) 0.23, 95% CI 0.16 to 0.29; number needed to harm
(NNH) 4, 95%CI 3 to 6). Other AEs commonly observedwith both the treatments
were blepharitis, cataract, dry eye, eye irritation, eye pain and keratitis. There was
no statistically significant difference for withdrawals due to AEs across both the
treatments (RD 0.02, 95% CI0.02 to 0.05). CONCLUSIONS: Timolol displayed a
better safety profile than latanoprost for adverse events including hyperemia, iris
pigmentation and pruritus. However, long term safety could not be assessed as few
included studies evaluated patients beyond six months.
Sensory Systems Disorders – Cost Studies
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MEDICAL CARE COSTS ASSOCIATED WITH VISION LOSS IN TAIWAN
Wang MT1, Ng K2, Lo YW1, Lee WJ1, Wu BJ1, Yeh WS3
1National Defense Medical Center, Taipei, Taiwan, 2Allergan Singapore Pte Ltd, Singapore,
Singapore, 3Allergan, Irvine, CA, USA
OBJECTIVES: To assess the economic burden from vision loss on the health care
system in Taiwan. METHODS: This is a retrospective matched cohort study, with
study population retrieved from the National Health Insurance Research Database
between 01/01/2000 and 12/31/2008. Based on the ICD-9-CM codes, cases initially
diagnosed with moderate vision loss (369.6-369.9), severe vision loss (369.1-369.4),
or blindness (369.0-369.08) were identified. Each case was matched to a randomly
selected control with normal vision by age ( 1 year) and gender. Each control was
assigned the same index date, the initial diagnosis date of vision loss, as the cor-
responding case. For each pair, the annual medical costs were calculated during
the one year after index date. All medical costs were adjusted to 2010 New Taiwan
dollars (NT$, US$1 
 NT$30). A generalized linear model with gamma distribution
and log-link was used to estimate the differences in post-index annual increased
costs while adjusting for baseline characteristics and pre-index logged costs. Boot-
strapping techniquewas used to generate 95% confidence interval (CI). RESULTS:A
total of 2,233, 283, and 350 patients with moderate vision loss, severe vision loss,
and blindness were identified, respectively. Patients with moderate vision loss,
severe vision loss, and blindness had NT$13,888 (CI 8,564-19,236), NT$23,768 (CI
7,764-42,379) andNT$75,461 (CI 56,123-94,685) higher annualmedical costs as com-
pared with their matched controls. Inpatient services (62.3%) constituted the larg-
est component of total medical costs for blindness, followed by outpatient services
(26.8%) and emergence care (4.3%). Similar patterns were observed for moderate
and severe vision loss. CONCLUSIONS: Consistent with the Western world, signif-
icantly higher medical costs are associated with vision loss in Taiwan. The addi-
tional costs seem to be related to the extent of the vision loss, with blindness
incurring the highest costs, followed by severe vision loss and then moderate vi-
sion loss.
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SYSTEMATIC REVIEW OF THE ECONOMIC LITERATURE ON ATOPIC
DERMATITIS IN CHILDREN
Iskedjian M1, Navarro V2, Khondoker F1, Farah B3
1PharmIdeas Research and Consulting, Oakville, ON, Canada, 2PharmIdeas Europe SAS, Lyon,
France, 3PharmIdeas Research and Consulting, Ottawa, ON, Canada
OBJECTIVES: A systematic review of the literature was performed to gather the
economic evidence related to atopic dermatitis (AD) in children.METHODS: OVID
MEDLINE® and EMBASE™ were explored by two reviewers for a combined search
with terms related to economics and quality of life in a paediatric population, for
the period 1996-2010. This abstract reports the results of the economic review. Two
reviewers browsed abstracts, retrieved the suitable articles, separated them into
cost of illness (COI) and economic evaluations including cost comparisons (CC),
cost-effectiveness (CEA) and cost-utility analyses (CUA), and summarized key
points. A third person acted as overall reviewer and adjudicator in case of
disagreement. RESULTS: From an initial search yielding 704 references, 16 articles
were included in the review, 7 COI and 9 economic evaluations, including 2 CC, 3
CUA and 1 CEA of treatment with immunomodulators, 1 CC of corticosteroids and
1CEAof homeopathy aswell as 1 CEA on a partially hydrolysed infant formula used
in prevention. The investigation period span from 1995 to 2010. Four studies were
performed in the UK, 3 in the US, 2 in Australia, 2 in Canada, 2 in Germany, 1 in
France, 1 in Italy and 1 covered 10 European countries. The range of yearly mean
cost for treating AD is very wide and increases according to severity. Themain cost
drivers seem to be consultations, hospitalizations, emollients and prescription
medications, as well as time loss for parents. CONCLUSIONS: Given its high prev-
alence, AD carries a substantial economic burden on such stakeholders as the
national healthcare systems and the family of the affected children. In light of
these findings, an approach based on prevention rather than treatment may have
a greater economic impact. In turn, further research is warranted on the potential
economic benefit from interventions aimed at prevention.
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COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR
CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING
Waycaster C
Healthpoint Ltd., Fort Worth, TX, USA
OBJECTIVES: To assess the cost-effectiveness of collagenase enzymatic debride-
ment relative to hydrogel autolytic debridement for pressure ulcers in a long-term
care setting. METHODS: A 2-stage Markov model was used to determine the ex-
pected costs of wound debridement between collagenase and hydrogel dressings
for pressure ulcers in a long-term care setting. The two Markov states used in the
analysis were a necrotic non-viable wound bed and a debrided viable wound bed.
Outcome data used in the analysis were taken from a randomized clinical trial that
directly compared collagenase and hydrogel dressings in a long-term care nursing
facility. The primary outcome in the clinical trial was the proportion of patients
achieving a viable, granulated wound bed at 42 days. Transition probabilities for
the Markov states were estimated from the clinical trial. Resource utilization was
based on the wound care treatment regimen used in the clinical trial. Resource
utilization costs were derived from standard cost references and medical supply
wholesalers. All costs are expressed in 2010 U.S. dollars. The payer perspectivewas
taken in the economic analysis and no cost discounting was performed due to the
short time horizon of the study. One-way and probabilistic sensitivity analyses
were performed to establish the robustness of the economic results. RESULTS: The
clinical trial established that 85% of the collagenase subjects versus 29% of the
hydrogel subjects achieved a debrided wound bed at the 42-day assessment.
The economic analysis indicated that 42 days after initiating treatment the cost-
effectiveness ratio for collagenase was $85 per debrided day compared to $184 per
debrided day using a hydrogel dressing. One-way and probabilistic sensitivity anal-
yses indicated that the results were robust within the modeled parameters.
CONCLUSIONS: Results indicate that collagenase ointment is cost effective for the
debridement of pressure ulcers compared to autolysis with a hydrogel dressing.
A54 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
